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. In view of these limitations and due to the increasing number of bone grafting procedures, surgeons are looking for more advanced therapies [6] [7] [8] [9] [10, 11] . Therefore, current research focuses on tissue engineering incorporating also (stem) cell therapy into the strategy. Although significant basic research has been generated about this issue, the practical transfer of this research into the clinical field deserves major attention from the European and world health authorities and the general public.
. The use of recombinant bone morphogenetic proteins (BMPs) has added another promising dimension to bone healing. Underpinned by solid scientific research, BMPs induce and promote critical steps of mostly endochondral bone formation. BMP devices have now been approved for clinical use in spinal fusion, non-unions and severely compromised long bone fractures. However, BMP technology has its limitations in particular when the microenvironment is compromised with poor or no vascularization
In this review, we explore the present status of (stem) cell based therapies with specific focus on human bone regeneration, and subsequent progress towards bone tissue engineering.
Present clinical targets under research in adults and children will be discussed. Finally, ethical issues and European regulations about the transfer of cell therapy research into patients with bone defects will be reviewed, with closing remarks about the present and future status of this remarkable resource.

Characterization of cells for bone regeneration in human beings
The novel field of regenerative medicine has recently expanded with the use of cells as effective therapeutic tools also for bone repair. These innovative medicinal products including mesenchymal stem cells (MSCs) , require an adequate regulatory framework, with the dual aim to promote development of new therapies to significant health problems and to protect the safety of the individuals to whom these products are administered. Besides safety, attention must be given to several scientific and technical aspects to set up standards for the final quality, and efficacy of these novel products. In particular, the possibility to produce a high number of MSCs from a single donor [12] and their potential lower immunogenicity [13] make them particularly attractive as 'off-the shelf' products, to be used in an autologous or in an allogeneic setting.
In this context, there is a need to guarantee the traceability of the product, from the donation of the starting material to the use of the final product perhaps in several different recipients. For these reasons, the regulatory agencies in different countries have chosen to adapt two consolidated sets of already existing rules to cellular products: the rules governing the pharmaceutical production and the regulation on the donation, manipulation and distribution of cells, tissues and organs. Thus, a new regulatory category of 'advanced therapy medicinal products' (ATMP) was proposed, finally going into effect by the end of 2007. In Europe, MSCs or combination products are thus considered ATMP, as defined by the European Regulation (European Commission [EC]) No. 1394/2007. ATMP include: (i) gene therapy medicinal products as defined in part IV of Annex I to Directive 2001/83/EC; (ii) somatic cell therapy medicinal products as defined in Part IV to Directive 2001/83/EC and (iii) tissue-engineered products, intended as products that contain or consist of engineered cells or tissues, and presented as having properties for, or administered to human beings in order to regenerate, repair or replace human tissues. MSCs may fall under EC No. 1394/2007 as somatic cell therapy products or tissue-engineered products depending on the source, manufacturing process and proposed indication for use. Due to the wide use of osteofixation biomaterials used for fracture and bone tissue repair, often in long-term contact with living bone tissue and cells, one clear-cut and specific issue related to the use of MSCs for bone repair is the possibility to use them in combination with biomaterials, thus identifying them as a typical tissue-engineered product. On the other hand, the EU Regulation is also in compliance with the 2004/23/EC directive on donation, procurement and testing of human cells and tissues and with directive 2002/98/EC on human blood and blood components.
Besides the need to guarantee the safety of the donor, the traceability from the donor to the recipient and the quality of the production process at any step, the main objective of these regulations is to obtain products with standards of pre-defined quality (quality control), depending on the identity of the product ( [16] . For BM, the age of the donor has been found to be inversely correlated to the yield of MSCs that can be obtained [17] , whereas controversial evidence has been reported for adipose tissue derived MSCs with regard to the age of the donor [18, 19] and to the site and the procedure used for harvesting [20] [25, 26] .
In [7, 8] . The sketch in Figure 1 [35, 36] . Recent experimental data have supported this new conceptual framework [37] .
To [39] . Our group has developed injectable bone fillers using silanized-cellulose hydrogels combined with solid CaP particles that gel in situ at physiological pH [40] . These pH sensitive cross-linking hydrogels may be used as artificial extracellular matrix for culturing various cell types [34] .
Bioceramics (Fig. 4) . bone graft in which situation the pseudo-membrane appears to increase the implantation yield, possibly also due to the local expression of cytokines and growth factors [41] . The 
Clinical targets for cell therapy in orthopaedics
Current clinical problems and therapeutic approaches
Potential clinical applications of cell based therapies for bone repair
30/39 patients, osseous union (77%). Fracture non-union, most recalcitrant group (union achieved in only 61%). Comparable to iliac crest autograft [57] 23 calcaneal unicameral cysts in 20 patients (av. FU of 49.4 months) Lyophilized irradiated chip allogeneic bone and autogenous BM (13 cysts in 11 patients). Percutaneous injection of irradiated allogeneic demineralized bone powder and autogenous BM (10 cysts in 9 patients).
Comparable results, advantage of safety for the percutaneous treatment.
[58] [65, 66] 
patients (79 hips) with acetabular defects at revision THR. 87% (69 hips), type III AAOS defects Standard frozen non-irradiated bone bank allograft (group A). Freeze-dried irradiated bone allograft, vitalized with autologous marrow (group B).
Results on incorporation of the allograft
Inborn errors of bone metabolism and cellular therapy
Plasticity, mineralization and bone remodelling are particularly important during childhood. The critical role of the balance between bone formation and bone resorption becomes evident in a number of inborn errors of bone metabolism [72] . Osteopetrosis was one of the first paediatric bone disorders in which molecular analysis identified the heterogeneous genetic background of a single clinical disorder [73] . This helped significantly to identify patients who will benefit from BM transplantation (BMT) [74, 75] . Although the hallmark of osteopetrosis is excessive bone mass, osteogenesis imperfecta is characterized by greatly reduced bone formation and severe fragility of these bones [76] . Interestingly, treatment by BMT in this disease was attempted much later [77] . However, in this disease, which is mainly caused by a collagen type I synthesis defect, not only haematopoietic stem cells became of interest, but also stromal cell populations [78, 79] . In fact, the first systemic application of isolated human MSCs was performed in osteogenesis imperfecta. Although the growth rate significantly improved during the first months and years, it slowed down subsequently [80] . This correlated with in vitro findings suggesting that systemic osteopoiesis is more difficult to achieve by current BMT strategies than haematopoiesis [81] . These limitations become evident, when children undergo BMT for inborn errors of metabolism, which affect several tissues, e.g. mucopolysaccharidosis [82, 83] . If the toxicity of BMT can be decreased in non-malignant diseases, this technique becomes the most promising alternative for novel cell therapy approaches [84] . Novel cell types and targeted conditioning regimens of reduced intensity will allow for systemic cellular therapies of inborn errors of bone metabolism [85, 86] .
Degenerative bone disorders in childhood
Osteonecrosis in paediatric patients is frequently caused by steroid-based therapies of haematological malignancies [87] . Furthermore [89] . Current treatment strategies aim primarily at elimination of pain, restoration of function and prevention of disease progression. Conservative measures are limited to immobilization and physiological rehabilitation, which is often complicated in children due to compliance problems [90] . Surgical measures include core decompression and ultimately prosthetic replacement. The outcome after core decompression is very variable and often dependent on risk factors, localization and surgical accessibility [91] [92] [93] . In order to improve the efficacy of core decompression, healthy BM or BM mononuclear cells from an aspirate at a distant site have been instilled in the interventions [68, 70, 94] . The most potent osteogenic cells in the BM known to date are MSCs [95] [96] [97] . Recent analyses of this population in the marginal zone of steroid-induced AVN showed a significant reduction in their numbers, viability and plasticity [67] . However, these cells are of critical importance for regenerating bony tissue via secretion of factors modulating the hypoxic and inflammatory environment as well as stimulating angiogenesis, which seems equally important for bone regeneration as the transdifferentiation of MSCs [98] . It is a matter of debate, whether MSCs may differentiate into tissues of interest, although this proof of principle has been verified in various animal model experiments [99] [100] [101] . In some studies, the beneficial effect of MSCs was rather attributed to the secretion of cytokines and growth factors at the site of injury [102, 103] [118] . The Declaration of Helsinki [119] 
Ethical aspects of EU clinical trials
Continuous development of the new fields in medicine led to a boost of studies involving both human samples and animal experiments used for clinical and preclinical trials. The European Union seeks to unify all the ethical and legal aspects regarding such concerns under a common framework, so that the design of the studies, procedures for their approval and other related issues would be similar throughout the Union. Current research activities in the field of human health raise various ethical concerns. Worldwide there is a continuing interest in ethical aspects, including research intervention and clinical trials conducted in human beings
Ethics related to information and consent
Persons who take part in the research are entitled to be informed about and to consent or not to clinical research [123] . EGE Opinion #15 [122] [127] . Clinical research represents a context with distinctive risk and benefit characteristics, which requires application of patient standard rather than professional standard regarding the uncertainty of the risks and the limited benefits to the patient [123] . [128, 129] . 
Ethics related to protection of the health of persons involved in clinical trials
Future directions and remarks
